In vitro activity of cefiderocol against Pseudomonas aeruginosa isolated from cystic fibrosis patients

Microbiol Spectr. 2023 Dec 12;11(6):e0304723. doi: 10.1128/spectrum.03047-23. Epub 2023 Nov 20.

Authors

Marguerite L Monogue^{1

2}, Dhara Desai³, Christine A Pybus³, James M Sanders^{1

2}, Andrew E Clark⁴, David E Greenberg^{2

3}

Affiliations

¹ Department of Pharmacy, University of Texas Southwestern Medical Center , Dallas, Texas, USA.
² Department of Internal Medicine, Infectious Diseases, and Geographic Medicine, University of Texas Southwestern Medical Center , Dallas, Texas, USA.
³ Department of Microbiology, University of Texas Southwestern Medical Center , Dallas, Texas, USA.
⁴ Department of Pathology, University of Texas Southwestern Medical Center , Dallas, Texas, USA.

No abstract available

Keywords: Pseudomonas aeruginosa; cefiderocol; cystic fibrosis; in vitro.

Publication types

Letter

MeSH terms

Anti-Bacterial Agents / pharmacology
Anti-Bacterial Agents / therapeutic use
Cefiderocol
Cephalosporins / pharmacology
Cystic Fibrosis* / complications
Cystic Fibrosis* / drug therapy
Humans
Microbial Sensitivity Tests
Pseudomonas Infections* / drug therapy
Pseudomonas aeruginosa

Substances

Cefiderocol
Anti-Bacterial Agents
Cephalosporins

Grants and funding

SRA202111-0005/Shionogi (Shionogi & Co. Ltd.)